Augmenting Exposure Therapy With an N-Methyl-D-Aspartate (NMDA) Agonist for Panic Disorder

Completed · Not applicable

Conditions studied: Panic Disorder

In brief

This study involves cognitive behavioral therapy (CBT) and a medication called D-cycloserine (DCS), which is thought to help reduce panic symptoms more effectively by interacting with N-methyl-D-aspartate (NMDA) glutamate receptors, facilitating many forms of learning including the extinction of fear. Participants will be randomly assigned (like flipping a coin) to receive either DCS or a placebo in addition to CBT.

Key facts

Study ID

NCT00131339

Run by

Hartford Hospital

People needed

40

Starts

2004-11-01

Expected to finish

2007-03-01

Last updated by the study team

2009-08-26

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Principal diagnosis of panic disorder

You may not qualify if…

• History of psychotic disorders or bipolar disorder
• Substance dependence
• Pregnant or breastfeeding
• History of a medical condition that may increase the risks of taking the study drug

Where it is running

• Hartford Hospital — Hartford, Connecticut, United States
• Center for Anxiety and Related Disorders at Boston University — Boston, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.